valsartan has been researched along with Pulmonary Arterial Remodeling in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Z; He, S; Li, J; Lu, Y; Peng, J; Shen, A; Wen, Y; Xie, Q; Yang, X; Zeng, W; Zhang, X | 1 |
| Choudhary, G; Clements, RT; Fernandez-Nicolas, A; Kue, NR; Mallem, K; Mancini, TJ; McCullough, DJ; Morrison, AR; Vang, A | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Chen, W; Dong, J; Gao, D; Guo, H; Lu, Y; Pan, X; Sun, Y; Xu, D; Xu, Y | 1 |
| Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; de Man, FS; Hyldebrandt, JA; Nielsen-Kudsk, JE; Nyengaard, JR; Ringgaard, S | 1 |
| Huo, Y; Lei, L; Mao, Y; Meng, L; Qi, Y; Su, J; Tang, C | 1 |
| Greenwood, JP; Negrou, K; Oliver, JJ; Plein, S; Ripley, DP; Struthers, AD; Worthy, G | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D | 1 |
| Bi, X; Li, S; Ma, X; Miao, Y; Su, G; Sun, H; Zhang, W; Zhang, Y; Zhao, Y; Zhong, M | 1 |
| Friedrich, S; Harazny, JM; Jumar, A; Kistner, I; Ott, C; Schmidt, S; Schmieder, RE | 1 |
| Ameer, OZ; Avolio, AP; Butlin, M; Kaschina, E; Phillips, JK; Sommerfeld, M | 1 |
2 trial(s) available for valsartan and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Thoracic; Bendroflumethiazide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Essential Hypertension; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Sympatholytics; Treatment Outcome; Valsartan; Vascular Remodeling; Vascular Stiffness | 2015 |
Effect of aliskiren on vascular remodelling in small retinal circulation.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Arterioles; Blood Pressure; Double-Blind Method; Essential Hypertension; Female; Fumarates; Humans; Hypertension; Laser-Doppler Flowmetry; Male; Middle Aged; Pulse Wave Analysis; Retinal Vessels; Valsartan; Vascular Remodeling | 2015 |
9 other study(ies) available for valsartan and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Neferine ameliorates hypertensive vascular remodeling modulating multiple signaling pathways in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Collagen; Hypertension; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulse Wave Analysis; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA; Signal Transduction; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2023 |
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial Pressure; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Female; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Neprilysin; Protease Inhibitors; Pulmonary Artery; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2019 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Topics: Animals; Blood Pressure; Cell Proliferation; Extracellular Matrix; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocrotaline; Phosphorylation; Rats, Sprague-Dawley; Systole; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2017 |
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Pulmonary Circulation; Rats; Tetrazoles; Valsartan; Vascular Remodeling; Ventricular Dysfunction, Right | 2019 |
Impaired regulator of G protein signaling 2 transcription facilitates vascular remodeling in injured rat aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Male; Muscle, Smooth, Vascular; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tetrazoles; Valine; Valsartan; Vascular Remodeling; Vascular System Injuries | 2014 |
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling | 2015 |
Valsartan blocks thrombospondin/transforming growth factor/Smads to inhibit aortic remodeling in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, High-Fat; Fibrosis; Male; Rats, Wistar; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Streptozocin; Thrombospondin 1; Time Factors; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2015 |
Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Blood Pressure; Cathepsin D; Cathepsin L; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hypertension; Kidney; Male; Matrix Metalloproteinase 9; NF-kappa B; Polycystic Kidney Diseases; Rats, Inbred Lew; Renal Insufficiency, Chronic; Time Factors; Valsartan; Vascular Remodeling; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2016 |